本刊首页 > 期刊目次 > 齐拉西酮与奥氮平治疗早期精神分裂症的疗效及安全性比较分析

• 文章 •

齐拉西酮与奥氮平治疗早期精神分裂症的疗效及安全性比较分析

  • 张建芳

* 通信作者: 张建芳, 单位:陕西省宝鸡市康复医院 721001

摘要

【摘要】
目的 对比齐拉西酮与奥氮平治疗早期精神分裂症的疗效及安全性。

方法 选取我院2016年1月至2017年8月间收治的72例早期精神分裂症患者作为此次研究对象,按照随机数字表法分为对照组与治疗组各36例,其中对照组给予奥氮平治疗,治疗组则接受齐拉西酮进行治疗。对比两组临床疗效、治疗前后精神病评定量表(BPRS)以及药物副作用评定量表(TESS)评分变化。

结果 治疗前两组患者BPRS评分对比差异均无统计学意义(P>0.05),治疗后两组BPRS评分较治疗前均有一定程度的降低,但治疗后2周、4周、6周时,组间BPRS评分差异对比无统计学意义(P>0.05),治疗8周后,治疗组BPRS评分较对照组明显更低;治疗后2周、4周、6周、8周时TESS评分均低于对照组,差异对比具有统计学意义(P<0.05);治疗前两组患者体质量及脂代谢相关指标总胆固醇以及LDL水平对比无统计学意义(P>0.05),治疗8周后,两组体质量、总胆固醇及LDL水平出现较大差异,对比具有统计学意义(P<0.05)。

结论 齐拉西酮与奥氮平治疗早期精神分裂症近期疗效相当,但奥氮平用药副作用稍高于对照组,对体质量及脂代谢相关指标影响更大,临床需根据实际情况合理选择。

关键词:齐拉西酮;奥氮平;精神分裂症;疗效;安全性

ABSTRACT

[Abstract]
Objective: To compare the clinical effect and safety of Ziprasidone and Olanzapine in the treatment of early schizophrenia. Method: 72 patients with early schizophrenia treated from January 2016 to August 2017 in our hospital were selected. The subjects were randomly divided into two groups, 36 cases each group. The control group took the Olanzapine; the treatment group took the Ziprasidone. The clinical effect, BPRS (Brief Psychiatric Rating Scale) points and TESS (treatment emergent symptom scale) points were compared. Result: Before treatment, the BPRS points for two groups were not significantly different (P>0.05);after treatment, the BPRS points were slightly reduced; after 2w, 4w and 6w of treatment, the BPRS points for two groups were not significantly different (P>0.05); after 8w of treatment, the BPRS points for treatment group were significantly lower than control group; after 2w, 4w, 6w and 8w of treatment, the TESS points for treatment group were significantly lower than control group (P<0.05);before treatment, the body mass index, total cholesterol and LDL for two groups were not significantly different (P>0.05);after 8w of treatment, the body mass index, total cholesterol and LDL for two groups were significantly different (P<0.05).

Conclusion  : Both of Ziprasidone and Olanzapine have a favorable effect in patients with early schizophrenia. Although Olanzapine has a higher adverse event rate, Ziprasidone produces a larger effect in the body mass index and lipid metabolism indicators. According to the patient’s condition, the proper therapy shall be selected in clinical practice.

Key words: Ziprasidone; Olanzapin; schizophrenia; clinical effect; safety

引用本文 / How to Cite This Article

张建芳.齐拉西酮与奥氮平治疗早期精神分裂症的疗效及安全性比较分析[J]. 国际精神病学杂志, , (): -

参考文献

相关文章